ClinicalTrials.gg
Not yet recruitingNCT07452341Updated Mar 11, 2026

Effect of Virtual Reality on Depression in Adolescent Females

An interventional study of Virtual reality headset and Selective serotonin reuptake inhibitors(SSRIs) in Depression, sponsored by Cairo University. Not yet recruiting. Open to female participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Depression by Cairo University — 7 open to participants now, 7 under way, none of them phase 3. Depression · Cairo University.

Planned enrollment
10th of 17
48 · median 50
Started
2026
with 4 others
No phase
16 of 20
6 open now
Registered
17th of 20
by date

Among the 20 studies in Depression by Cairo University, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, and was the 17th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

7 of the 20 studies in Depression by Cairo University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 13 Years to 18 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Depression by Cairo University, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of virtual reality on depression in adolescent females.

Read the detailed description

Depression is most commonly found in adolescents and large percentage of them don't receive management.

People with depression usually experience at least five of the following 9 characteristics: (1) people feel sad and unhappy; (2) have less interest in doing things; (3) individuals do not follow a diet, but their weight losses are obvious; (4) their appetites change and their weight may increase; (5) they suffer insomnia or drowsiness; (6) some people have mental agitation; (7) they feel that life is meaningless, or they feel guilty; (8) they have difficulty concentrating; or (9) they have suicidal thoughts . Individuals who develop depression may have experienced an anxiety disorder earlier in life.

Depression is most commonly found in adolescents and large percentage of them don't receive management The application of emerging technology in health promotion has generated substantial public interest. Among the emerging technologies that may potentially aid in the treatment of depression, virtual reality (VR) is the most exciting and technologically-advanced.

A virtual environment provides a greater degree of control for the therapists to customize, reproduce, and tweak several treatment parameters according to the patient's needs.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescent females suffer from depression who are diagnosed and referred by the psychiatrist.
  • Their ages will range from 13-18 years old
  • Their will range from 15.5 -24.9 kg/m2
  • They are interested in their mental state or with depressive disorders and their score on Beck depression inventory (BDI) between 11-30 (mild to moderate depression)
  • They are interested in using VR technology to improve mental health problems.

Exclusion criteria

Exclusion Criteria:

  • Patients who suffer from major diseases other than depression.
  • Adolescents who are not interested in VR.
  • Patients with severe mental illness or repetitive suicidal trials .
  • Patients who receive any other psychotherapy.
  • Obese patients with more than 26.2 -29.5kg/m2
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Drug + virtual reality group

    24 Participants in this group will receive the same standard drug therapy(Selective serotonin reuptake inhibitors(SSRIs) in addition to virtual reality exposure using VR headset during the treatment sessions.

    Device: Virtual reality headset · Drug: Selective serotonin reuptake inhibitors(SSRIs)

  • Active comparator
    Drug only group (controlled)

    24 participants will receive antidepressant drugs Selective serotonin reuptake inhibitors(SSRIs) only

    Drug: Selective serotonin reuptake inhibitors(SSRIs)

Interventions

  • DeviceVirtual reality headset

    Participants will use virtual reality glasses during treatment sessions for approximately 30 minutes per session, once per week for 8 weeks .

  • DrugSSRIsStudies of SSRIsSSRIs pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All adolescent females in the control group will receive antidepressant drugs Selective serotonin reuptake inhibitors(SSRIs) for 8 weeks as described by the psychiatrist

06

What researchers measure

Primary outcomes

  1. 1-Calculation the score of Beck Depression Inventory [BDI] to assess the severity of depression.

    Beck depression scale assess depression levels in both groups (A\&B) before and after the end of the study. It is a self-administered questionnaire containing 21 items which takes about five minutes to be complete. Patients will be asked to complete the questionnaire, add up the score for each of the twenty-one questions by counting the number to the right of each question she marked. The highest possible total for the whole test is sixty-three this mean patient circled number three on all twenty-one questions, the lowest possible score for each question is zero, this mean she circled zero on each question

    Time frame: 8 weeks

  2. 2-Calculation the score of KIDSCREEN-52 questionnaire to assess the quality of life

    KIDSCREEN-52 questionnairet consists of 52 itemes that can measure the following 10 dimensions: Physical Well-Being (5 items), Psychological Well-Being (6 items), Moods and Emotions (7 items),Self-Perception (5 items), Autonomy (5 items),Parent Relations and Home Life (6 items), Financial Resources (3 items), Peers and Social Support (6 items),School Environment (6 items) and social acceptance( Bullying) (3 items). It has high validity and reliability. Patients will be asked to complete the questionnaire,scores are computed for each dimension and are transformed into T-values with a mean of 50 and a standard deviation of 10; a low score indicates a poor QOL and higher score indicates higher QOL and wellbeing

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 5, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07452341
Lead sponsor
Cairo University
Responsible party
Heba Mohamed Abdelhaleem Hassan (Principal investigator, Cairo University) — Principal investigator
First posted
Mar 5, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Mar 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion